ABSTRACT
Multiple sclerosis [MS] typically affects young adults; however, the first symptoms can occur after age 50 and is classified as late-onset MS [LOMS]. In this retrospective study, we extracted the records of 3522 MS patients [2716 females and 806 males] registered in the Isfahan MS Society [IMSS] from 2003 to 2010. Next, we searched for LOMS cases. We aimed to compare these cases with 1698 non-LOMS subjects also extracted from the IMSS database. We found 48 LOMS patients [28 females and 20 males], which gave a crude frequency of 1.36%. The frequency by sex of LOMS in males [2.4%] was significantly greater than in females [1.0%, P = 0.002]. The mean age at onset was 55.1 +/- 4.3 years. The female to male ratio of 1.4:1 in these patients was significantly lower than in non-LOMS subjects [3.37:1, P= 0.003]. The leading pattern of MS was relapsing-remitting [RR] in 62.5%, followed by primary progressive [PP] in 27.1%, and secondary progressive [SP] in 10.4%. Predominant presenting symptoms and signs were motor disturbances [35.4%], followed by brainstem [25%], optic neuritis [22.9%], and sensory related deficits [18.7%]. The mean progression index [PI] in LOMS patients [0.88 +/- 0.48] was significantly higher than in non-LOMS cases, 0.37 +/- 0.17 [P< 0.0001]. In comparing LOMS patients with the non-LOMS cohort, there was a higher frequency of the PP pattern and a higher PI in the LOMS group. In comparing other high-risk populations with the Isfahan cohort, LOMS formed a lower percentage of the total Isfahan MS population
Subject(s)
Humans , Male , Female , Age of Onset , Retrospective StudiesABSTRACT
Multiple Sclerosis [MS] is an inflammatory demyelinating and neurodegenerative disorder of the central nervous system [CNS], which mainly affects young adults. Activated T lymphocytes promote the neuro-inflammatory cascade of MS by secreting pro-inflammatory cytokines and play a significant role in its pathogenesis. T lymphocytes may trigger the inflammation, which in turn leads to axonal loss and neurodegeneration observed in the course of MS. Currently, there is no cure for MS, however, one of the most promising neuroprotective research tools consists of the use of bone marrow derived mesenchymal stem cells [MSC]. This method promotes immune system regulation and possibly induces neurological repair and re-myelination of the damaged axons. Recent studies have shown that MSC exert an immune regulatory function and induce T regulatory-cell proliferation, therefore, it may serve as a potentially useful treatment for immune-mediated diseases such as MS. In this pilot study a group of MS patients underwent MSC therapy and we assayed the expression of an X-linked transcription factor, FoxP3, as a specific marker of T Regulatory cells in peripheral blood, prior to and after the treatment. Using q RT-PCR for measurement of expression of FoxP3 by peripheral blood mononuclear cells, we found that in all subjects, except for one, the expression of FoxP3 at 6 months after intrathecal injection of MSC was significantly higher than the levels prior to treatment. Such significant enhanced expression of FoxP3 associated with clinical stability. Findings from this pilot study further support the potential of bone marrow derived MSC for treatment of MS patients